Merck & Co., Inc.'s Vioxx Heart Risk Persists One Year After Stopping Use, University of Texas MD Anderson Cancer Center Study

Medical News Today -- A new international study found that Merck’s pain killer Vioxx (rofecoxib), which the drug company voluntarily withdrew from the market in 2004, found that a near two-fold increased risk of heart, stroke and death persisted for up to one year after stopping use.

MORE ON THIS TOPIC